The Bethesda system for reporting thyroid cytopathology
In order for pathologists to better communicate thyroid FNA interpretations to referring physicians, the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was developed in 2007 (Cibas and Ali 2009) . The 2007 National Cancer Institute (NCI) conference and 2009 35th European Congress of Cytology (ECC) reviewed and discussed 6 topics (Cibas and Ali 2009): (1) indications for thyroid FNA and pre-FNA requirements; (2) training and credentialing; (3) techniques for thyroid FNA; (4) diagnostic terminology and morphologic criteria; (5) utilization of ancillary studies in thyroid FNA; and (6) post-FNA testing and treat-pre-FNA requirements, training specifications, criteria for the selection of patients to undergo FNA, diagnostic categories and criteria, ancillary testing and post-FNA follow-up and treatment options. TBSTRC classified thyroid FNA findings into 6 categories (Table 1) (Cibas and Ali 2009 
Category: Nondiagnostic/unsatisfactory
To be satisfactory for evaluation, a specimen should contain at least 6 groups of benign follicular cells and at least 10 cells in each group (Grant, Hay et al. 1989; Haider, Rakha et al. 2011) , except for findings consistent with colloid nodule (Cibas and Ali 2009) . Nondiagnostic/unsatisfactory cases should account less than 10% with a range from 2 -20% of cases (Cibas and Ali 2009) . Postoperative risk of malignancy in thyroid nodules with nondiagnostic cytology is 12% on average with a range from 0 -32% (Cibas and Ali 2009; Wang, Friedman et al. 2010) . The risk of malignancy for a cyst fluid only sample is 4% (Renshaw 2001) . A repeated FNA aspiration with ultrasound guidance is recommended for nondiagnostic/unsatisfactory and clinically or sonographically worrisome cyst fluid only cases, and is diagnostic in 50 -88% of cases (Renshaw 2001; Cooper, Doherty et al. 2009 ). Aspirates composed of pure colloid and lacking a cellular component should be considered benign rather than non-diagnostic (Layfield, Cibas et al. 2010 ).
Category: Benign
The FNA smears of hyperplastic/adenomatoid nodules typically show bland follicular cells as well as metaplastic Hürthle cells arranged in macrofollicles, normofollicles, and possibly microfollicles, and show moderate to abundant colloid ( Figure 1 ). Abundant macrophages including hemosiderin-laden macrophages, proteinaceous material, hemolyzed red blood cells, reactive follicular cells, and stromal cells may be seen. FNA results with benign cytology should account for 67 -70% of cases (Cibas and Ali 2009) . Postoperative risk of malignancy in thyroid nodules with benign cytology should be approximately 5% with a negative predictive value (NPV) of 95% according to the 2009 American Thyroid Association (ATA) guidelines (Cooper, Doherty et al. 2009 ) and 0 -3% according to the 2007 TBSRTC (Layfield, Cibas et al. 2010) . Other studies showed an average of 6% with a range from 1 -18% (Cibas and Ali 2009; Lewis, Chang et al. 2009; Wang, Friedman et al. 2010) . Further immediate diagnostic studies or treatment are not routinely required (Cooper, Doherty et al. 2009 ). Some authors suggested that patients be followed up with repeated assessment by palpation or ultrasound at 6-to 18-month intervals and should be followed-up for at least 3 -5 years (Layfield, Abrams et al. 2008; Cooper, Doherty et al. 2009 ). If the nodule shows significant growth (20% increase in nodule diameter with a minimum increase in two or more dimensions of at least 2 mm (Cooper, Doherty et al. 2009)) or shows "suspicious" sonographic changes, a repeated FNA is considered.
Category: Atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS)
AUS/FLUS includes cases in which the cytomorphologic findings are not representative of a benign lesion such as a hyperplastic⁄adenomatoid nodule, yet the degree of cellular or architectural atypia is not sufficient to render an interpretation of follicular neoplasm⁄suspicious for a follicular neoplasm or suspicious for malignancy. This diagnosis may also be used in thyroid FNA specimens that are less than optimal due to limited cellularity, poor fixation and presence of obscuring blood. AUS cases account for 3 -6% of thyroid FNAs (Yang, Schnadig et al. 2007 ; Yassa, Cibas et al. 2007) . Postoperative risk of malignancy in nodules with atypical cytology is 16% on average with ranges from 5 -48% (Cibas and Ali 2009; Wang, Friedman et al. 2010) , and 5 -15% according to 2007 TBSRTC (Layfield, Cibas et al. 2010) . Patients with AUS cytology should be managed by undergoing an iodine 123 scan, especially if serum TSH level is low. If the scan is "hot", clinical follow-up with a repeated FNA in 3 -6 months is recommended (Yassa, Cibas et al. 2007; Cibas and Ali 2009; Layfield, Cibas et al. 2010) . Repeat FNA will result in definitive interpretation in most of cases, however a repeat diagnosis of AUS occurs in about 20% of cases (Yassa, Cibas et al. 2007) . If the scan is "cold", the patient should be referred for surgery.
Category: Follicular neoplasm or suspicious for a follicular neoplasm
The category of follicular neoplasm or suspicious for a follicular neoplasm identifies a nodule that might be a follicular carcinoma (FC) and triages it for surgical lobectomy (Cibas and Ali 2009) . The FNA smears are typically highly cellular, composed of abundant larger follicular cells arranged in microfollicles or trabeculae with crowding and nuclear overlapping, and have scant colloid (Figure 3 ) (Cibas and Ali 2009) . FNA cytology cannot distinguish follicular carcinoma from benign follicular adenoma and sometimes adenomatoid nodule, because distinguishing a follicular carcinoma from follicular adenoma is based on identification of capsular invasion or vascular invasion of in the capsule. Distinguishing a follicular adenoma from adenomatoid nodule is based on the identification of entire capsulation. Diagnosis of follicular variant of papillary carcinoma is based on nuclear features, which, sometimes, is challenging. This category accounts for 9 -30% of FNA specimens (Hegedus 2004; Mihai, Parker et al. 2009 ). Most cases in this category are benign follicular adenomas or adenomatoid nodules (up to 35%) (Yang, Schnadig et al. 2007 ). Postoperative risk of malignancy is 25% on average with a range from 14 -49% (Cibas and Ali 2009; Wang, Friedman et al. 2010) , and is 15 -30% according to 2007 TBSRTC (Layfield, Cibas et al. 2010) . Some cases are follicular carcinoma and others are follicular variant of papillary carcinoma (Yassa, Cibas et al. 2007 ). Hürthle cell variant should be specified due to different underlying genetics from follicular neoplasms. About 16% -25% cases of Hürthle cell variant in this category are proven to be hyperplastic proliferations of Hürthle cells in nodular goiter or lymphocytic thyroiditis (Giorgadze, Rossi et al. 2004; Pu, Yang et al. 2006) . About 15% to 45% of nodules are malignant, and the remainder of the neoplasms prove to be Hürthle cell adenomas (Giorgadze, Rossi et al. 2004; Pu, Yang et al. 2006) . If the reading is "Hürthle cell neoplasm", either lobectomy/hemithyroidectomy or total thyroidectomy is recommended. When diagnosed by FNA as either Hürthle cell neoplasm or Hürthle cell lesion, males are much more likely to have malignant tumors than females (Wu, Clouse et al. 2008 ).
Category: Suspicious for malignancy
The "suspicious" category is used for those cases that show some nuclear features of papillary carcinoma or other malignancies, or have scant diagnostic cells due to sampling reason or small tumor (papillary microcarcinoma), but are not enough for diagnosis of malignancy. Postoperative risk of malignancy in thyroid nodules with suspicious for malignancy is 62% on average with a range from 42 -87%, and is 65 -75% according to 2007 TBSRTC (Layfield, Cibas et al. 2010) . The rest are usually follicular adenoma (Yang, Schnadig et al. 2007 ; Yassa, Cibas et al. 2007; Cibas and Ali 2009; Wang, Friedman et al. 2010) . Nodules called suspicious for papillary carcinoma are resected by lobectomy, near total thyroidectomy, or thyroidectomy (Cooper, Doherty et al. 2009; Layfield, Cibas et al. 2010 ).
Category: Malignant
The category of malignancy is used whenever the cytomorphologic features are conclusive for a malignancy. The diagnosis of papillary thyroid carcinoma by FNA biopsy depends on nuclear features of follicular cells (enlarged and elongated nuclei with nuclear pseudoinclusion, nuclear grooves, powdery chromatin), and architectures (papillary versus follicular) ( Figure 4 ). Other FNA features include psammomatous calcification, and "gum"-like thick colloid. The characteristic FNA features of undifferentiated (anaplastic) carcinoma are presence of pleomorphic, markedly atypical spindle cells ( Figure 5 ). The FNA features of thyroid medullary carcinoma are presence of pleomorphic polygonal tumor cells with characteristic neuroendocrine nuclear features "(salt and pepper") and granular cytoplasm, which are present in a single cell pattern, loosely cohesive clusters, follicular and papillary architecture ( Figure 6 ). Serum calcitonin screening is useful in detection of C-cell hyperplasia and medullary thyroid cancer. Large cell lymphoma is the predominant subtype, and consists of relatively monotonous populations of large, abnormal lymphoid cells (Morgen, Geddie et al. 2010) . Marginal zone lymphoma is composed of small lymphocytes with plasmacytoid features (Morgen, Geddie et al. 2010 ). Amyloidosis may be seen. The FNA features of metastatic malignancies vary depending on the primary organs and subtypes ( Figure 7 ). Approximately 3% to 7% of thyroid FNAs have conclusive features of malignancy, and most are papillary carcinomas (Yang, Schnadig et al. 2007; Cibas and Ali 2009) . Postoperative risk of malignancy in thyroid nodules with malignant cytology averages 97% with a range from 93-100% (Cibas and Ali 2009; Layfield, Cibas et al. 2010; Wang, Friedman et al. 2010) . Of the differentiated cancers, papillary cancer comprises about 85% of cases, follicular carcinoma comprises about 10%, and Hürthle cell carcinoma comprises 3% (Hundahl, Fleming et al. 1998) . Lobectomy for follicular carcinoma and Hürthle cell carcinoma and near total and total thyroidectomy for papillary thyroid carcinoma is recommended. Postoperative radioiodine (RAI) remnant ablation is increasingly being used to eliminate the postsurgical thyroid remnant (Hay, Thompson et al. 2002) . Thyroidectomy is not usually used for metastatic tumors, non-Hodgkin lymphomas, and undifferentiated carcinomas ( and cohesive clusters (D), with enlarged and elongated nuclei containing fine granular chromatin (powering), nuclear pseudoinclusion and nuclear grooves, and slightly dense cytoplasm (squamoid). Psammomatous calcification (C) and "chewing gum" dense colloid are seen (B).
www.intechopen.com 2007 TBSRTC has been demonstrated to be excellent for reporting thyroid FNAs (Theoharis, Schofield et al. 2009 ). Each diagnostic category conveys specific risks of malignancy, which offers guidance for patient management. Routine second opinion review of indeterminate thyroid FNA biopsies can potentially obviate the need for diagnostic thyroidectomy in 25% of patients without increases in false negatives (Davidov, Trooskin et al. 2010) . Routine second opinion review of FNA specimens increases sensitivity, specificity, positive predictive value, and negative predictive value (Tan, Kebebew et al. 2007 ).
Immunohistochemistry used in thyroid lesions
Immunohistochemical (IHC) stains are seldom used in thyroid FNA biopsy for follicular lesions. IHC can be performed on FNA cellblock or FNA smears. Thyroid follicular neoplasms and medullary carcinomas are positive for TTF-1. Conventional papillary thyroid carcinoma is immunoreactive for p53 (76%), galectin-3 (100%), and EMA (50%), while are negative for p63 (Koo, Shin et al. 2010) . Diffuse sclerosing variant of papillary carcinoma is immunohistochemically positive for p63 (28.6%), p53 (42.9%) galectin-3 (16.3%), EMA (40.8%) (Koo, Shin et al. 2010) , and BCL-2 (Koo, Shin et al. 2010) . Medullary thyroid carcinoma is positive for calcitonin. Immunohistochemical stains for CD3, CD20, CD79a, PAX-5, CD5, CD10, CD23, cyclin D1 (BCL-1), BCL-1, BCL-6, alpha or lambda light chain, and other lymphoid markers are useful for diagnosis of lymphoma (Morgen, Geddie et al. 2010) . Aliquot of FNA aspiration should be sent for flow cytometry analysis.
Molecular tests used in thyroid nodular lesions
Molecular tests can be performed on FNA specimens and can help in diagnosis and classification of thyroid nodules (Chudova, Wilde et al. 2010 ). Many molecular markers (e.g., galectin-3 (Bartolazzi, Orlandi et al. 2008; Kato and Fahey 2009) , cytokeratin, BRAF (Lin, Liu et al. 2006; Pizzolanti, Russo et al. 2007; Sapio, Posca et al. 2007; Kato and Fahey 2009; Nikiforov, Steward et al. 2009 ), RAS (Nikiforov, Steward et al. 2009 ), RET/PTC (Pizzolanti, Russo et al. 2007; Sapio, Posca et al. 2007; Kato and Fahey 2009; Nikiforov, Steward et al. 2009 ), TRK (Sapio, Posca et al. 2007 ), Pax8-PPARγ (Kato and Fahey 2009; Nikiforov, Steward et al. 2009 ), HBME-1(Kato and Fahey 2009), hTERT (Kato and Fahey 2009) , miRNA (Kato and Fahey 2009 ), LOH at 10q23 (Lin, Liu et al. 2006) ) have been evaluated to improve diagnostic accuracy for indeterminate nodules (Sapio, Posca et al. 2007; Bartolazzi, Orlandi et al. 2008) . Recent large prospective studies have confirmed the ability of genetic markers (BRAF, Ras, RET=PTC) and protein markers (galectin-3) to improve preoperative diagnostic accuracy for patients with indeterminate thyroid nodules diagnosed by FNA biopsy (Pizzolanti, Russo et al. 2007; Sapio, Posca et al. 2007; Bartolazzi, Orlandi et al. 2008; Franco, Martinez et al. 2009; Nikiforov, Steward et al. 2009 ). It is likely that some combination of molecular markers will be used in the future to optimize management of patients with indeterminate cytology on FNA specimens. BRAF mutations occur in approximately 44% (from 29 to 83% of papillary carcinoma, and can be used in diagnosis and as a target of treatment (Lassalle, Hofman et al. 2010) . With more and more basic and clinical translational research, molecular tests as an adjunctive diagnostic tool will increase the diagnostic accuracy of FNA biopsy with cytologic diagnoses of AUS/FLUS, follicular neoplasm/suspicious for follicular neoplasm, and suspicious for malignancy. However, molecular markers (Galectin-3, CITED1, HBME-1, Ras, RET/PTC, and PAX8/PPARγ) have been identified in some histopathologically classified benign nodules (Arora, Scognamiglio et al. 2008) . Follicular adenomas and Hürthle cell adenomas have similar gene expression profile as malignant tumors (Arora, Scognamiglio et al. 2008) . By detection of BRAF mutation and loss of heterozygosities (LOH), 66.7% papillary thyroid carcinomas (PTC), including 50% papillary microcarcinoma cases (<1 cm), were proved to be intrathyroid metastasis (Lin, Finkelstein et al. 2008) . Patients with intrathyroid metastasis, including papillary microcarcinoma, had significantly increased lymph node metastasis (Lin, Finkelstein et al. 2008 ). LOHs of 17q21, 17p13, 10q23 and 22q13 may be important in predicting increased risk of lymph node metastasis (Lin, Finkelstein et al. 2008 ). LOH of 9p21 was found at the highest frequency in PTC (53.8%), followed by 1p36 (46.2%), 10q23 (34.6%), and 22q13 (34.6%) (Lin, Finkelstein et al. 2008 ). Papillary microcarcinoma had acquired similar genomic mutations as conventional PTC (>1 cm), but higher frequencies of mutations of B-RAF, 1p36, 18q, and 22q13 were found in the larger PTC, suggesting that they might play a role in the aggressiveness of PTC (Lin, Finkelstein et al. 2008) . Different profiles of mutations were observed in conventional, follicular variant, and diffuse sclerosing variant of PTC, which might influence the different morphological appearances and clinical courses (Lin, Finkelstein et al. 2008) . Therefore, molecular analysis can separate multifocal independent primary PTC from intrathyroid metastatic PTC, and may be more important than tumor size in predicting lymph node metastasis, aggressiveness, and prognosis of PTC (Lin, Finkelstein et al. 2008) . Microarray analysis has be used in thyroid FNA specimens (Lubitz, Ugras et al. 2006 ).
Clinical workup of parathyroid lesions

Introduction
Primary hyperparathyroidism is a common problem encountered in clinical practice. Patients commonly present with elevated serum and urine calcium and parathyroid www.intechopen.com hormone (PTH) concentration. In most cases, the diagnosis is relatively straightforward. However, when imaging studies fail to localize the parathyroid adenoma or hyperplasia, management can be challenging. The gold standard to determine the cause of primary hyperparathyroidism is bilateral neck exploration. Minimally invasive parathyroidectomy is the preferred treatment of choice, but it requires the accurate localization of a parathyroid lesion by ultrasound imaging, Tc 99 -sestamibi scan, and FNA combined with PTH test. Minimally invasive parathyroidectomy is not applicable in those patients who have coexisting thyroid cancers or nodules with suspicious cytology (Abraham, Duick et al. 2008 ) .
Clinical workup of parathyroid lesions
Ultrasound imaging and/or Tc 99 -sestamibi scan are used to localize the abnormal parathyroid glands. For the detection of the incidentalomas, the positive predictive value (PPV) of thyroid ultrasound was 21.4% (Kwak, Kim et al. 2009 ). In the overall patients, the sensitivity and PPV of ultrasound, Tc 99 -sestamibi scan, and ultrasound + Tc 99 -sestamibi scan to localize parathyroid adenoma are 96% and 91%, 92% and 87%, and 95% and 94%, respectively (Erbil, Salmaslioglu et al. 2007 ). FNA biopsy is seldom used in evaluation of parathyroid lesions, especially those that can be visualized by ultrasound. Some authors suggested that FNA is valuable in patients who have a nondiagnostic Tc 99 -sestamibi scan, with multiple enlarged parathyroid glands, prior failed surgery, differentiating parathyroid adenomas from posterior thyroid nodules, atypical location, and nonfunctioning parathyroid incidentalomas (Abraham, Duick et al. 2008; Vu and Erickson 2010) . Cellular FNA specimens with features not typical for thyroid lesions should be triaged for PTH assay in the FNA rinse, which is useful to differentiate parathyroid lesions from thyroid lesions (Owens, Rekhtman et al. 2008; Ciuni, Ciuni et al. 2010; Lieu 2010 ). This technique is also used during operation (Lamont, McCarty et al. 2005 ).
Fine needle aspiration biopsy of parathyroid lesions
For the detection of the incidentalomas, the sensitivity of ultrasound guided FNA was 41.7%, specificity was 97.7%, accuracy was 85.7%, PPV was 83.3%, and negative predictive value (NPV) was 86% (Kwak, Kim et al. 2009 ). The sensitivity of FNA-parathyroid hormone test was 92.9%, specificity was 100%, accuracy was 94.4%, PPV was 100%, and NPV was 80% (Kwak, Kim et al. 2009 ). Overall, the sensitivity and positive predictive value of FNA-PTH assay to localize parathyroid adenoma is higher compared with ultrasound, Tc 99 -sestamibi scan, and ultrasound + Tc 99 -sestamibi scan (Erbil, Salmaslioglu et al. 2007 ). FNA aspirates of parathyroid lesions are often cellular (Absher, Truong et al. 2002; Owens, Rekhtman et al. 2008) . FNA cytomorphologic features include small and monotonous to moderately anisokaryotic cells that are present in cohesive cellular disorganized sheets, cords, cohesive three-dimensional groups, papillary fragments, and microfollicles (in 90% of parathyroid adenomas and absence in parathyroid hyperplasia), have round to oval hyperchromatic nuclei containing finely to coarsely granular chromatin and inconspicuous nucleoli, and have fragile, pale blue or finely granular cytoplasm with ill-defined borders (Absher, Truong et al. 2002; Liu, Gnepp et al. 2004; Owens, Rekhtman et al. 2008 ) (Figure 8 ). Isolated cells and naked nuclei are commonly present and sometimes predominate (Absher, Truong et al. 2002; Liu, Gnepp et al. 2004; Owens, Rekhtman et al. 2008) , and rare case shows lymphoid-like smears (Absher, Truong et al. 2002) . Prominent nucleoli, mitotic figures, and karyolysis are seen in parathyroid carcinoma (Hara, Oyama et al. 1998 ). Nuclear pleomorphism is seen in 33% of parathyroid adenoma and absent in parathyroid hyperplasia (Liu, Gnepp et al. 2004) . A granular smear background is usually present (Owens, Rekhtman et al. 2008) . Oncocytic parathyroid adenoma is a rare benign neoplasm. It is challenging to distinguish from thyroid Hürthle cell lesion on FNA biopsy, and may be misinterpreted as suspicious for Hürthle cell neoplasm (Paker, Yilmazer et al. 2010) or Hürthle cell neoplasm. FNA reveals cellular smears containing monotonous oncocytic cells arranged in monolayered sheets, pseudopapillary structures and clusters within a rich vascular network (Paker, Yilmazer et al. 2010) . Fig. 8 . Parathyroid adenoma, FNA cytology, modified Giemsa (A) and Papanicolaou stain (B), 600x. FNA smears show small and monotonous epithelial cells that are present in cohesive cellular disorganized sheets, three-dimensional groups and microfollicles, have round to oval hyperchromatic nuclei containing finely to coarsely granular chromatin and inconspicuous nucleoli, and have fragile, pale or finely granular cytoplasm with ill-defined borders.
Parathyroid cysts (PCS) are rare and rarely symptomatic except for swelling. PCS are divided into functional (hyperparathyroidism, hypercalcemia, and hypophosphatemia) and non-functional PCS that represent about 10% of PCS. The non-functional PCS are considered true PCS because their wall is lined by secretory epithelium, and the functioning PCS develop due to cystic degeneration of parathyroid gland adenomas. The ultrasound images demonstrate a cystic lesion. FNA aspirates clear liquid, which should be sent to chemistry laboratory to test PTH level (Absher, Truong et al. 2002; Ciuni, Ciuni et al. 2010; Lieu 2010) . The first treatment is the aspiration FNA, which can be curative, but recurrences can be treated surgically (Ciuni, Ciuni et al. 2010) . FNA of parathyroid adenomas may cause severe fibrosis complicating surgery and final histologic diagnosis (Norman, Politz et al. 2007 ), which could be avoided by using fine bore needles (25 -27 gauge) and fewer passes (1 to 2 passes) (Abraham, Duick et al. 2008) . Needle track implantation of parathyroid carcinoma has been reported, although it is extremely rare (Agarwal, Dhingra et al. 2006) .
Immunohistochemistry in parathyroid lesions
IHC stains for PTH, synaptophysin, chromagranin, NSE, and CD56 can be performed on FNA smears and cellblock for confirmation of parathyroid origin. The FNA cytomorphology of parathyroid adenoma shares some features with thyroid lesions, which may lead to misinterpretation as thyroid follicular lesion/neoplasm, medullary carcinoma, papillary carcinoma, and thyroid cyst (Absher, Truong et al. 2002; Owens, Rekhtman et al. 2008; Lieu 2010) . Therefore, a PTH assay of needle rinse and IHC studies should be ordered for any case with an FNA cytomorphology that is not typical for thyroid lesion, PCS develop due to absence of colloid, and is a highly cellular specimen.
Clinical workup of adrenal glands 4.1 Introduction
Adrenal gland is the fourth most frequent site of spread of tumors after lungs, liver, and bone (Willis 1973; Lloyd, Kawashima et al. 2004) . Metastatic malignancies are far more common than primary malignancies of the adrenal gland (Lloyd, Kawashima et al. 2004 ). Adrenal metastases develop in 27% of patients dying with carcinomas (Abrams, Spiro et al. 1950; Lloyd, Kawashima et al. 2004) . The most common primary sites are the breast, lung, kidney, stomach, pancreas, ovary, and colon. Adrenal glands are also often involved by disseminated infectious diseases. The commonly encountered primary adrenal neoplasms include myelolipoma (2.5% of primary tumors) (Lam and Lo 2001) , cortical adenoma (incidence, 1.5 -7%) (Stewart 2002) , cortical carcinoma (incidence, 1/1 million/year) (Lloyd, Tischler et al. 2004) , and pheochromocytoma. Eighty five percent of adrenal cortical adenomas are nonfunctional (Stewart 2002) , while 80% of adrenal cortical carcinomas are functional (Lloyd, Tischler et al. 2004) . Adrenal cortical carcinoma is also associated with Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, and Carney complex. Pheochromocytoma is generally associated with clinical symptoms due to overproduction of catecholamines, intermittent, paroxysmal hypertension accompanied by sweating, palpitations, headache, diaphoresis, nervousness, nausea, vomiting, weakness, abdominal or chest pain.
Fine needle aspiration biopsy of adrenal lesions
FNA is often used to evaluate nodular or mass lesions of adrenal glands under the guidance of CT scan, ultrasound, EUS, and MRI scan. Application of FNA biopsy for incidentally discovered adrenal masses (incidentaloma) is controversial (Nurnberg 2005; Lumachi, Borsato et al. 2007; Quayle, Spitler et al. 2007) . A thorough clinical history and radiographic studies (CT scan, MRI and norcholesterol scintigraphy) are very important in the workup (Lumachi, Borsato et al. 2007) . It may be difficult in some cases for FNA to distinguish benign (non-neoplastic or adenoma) from malignant adrenal cells with certainty (Tikkakoski, Taavitsainen et al. 1991) , although a report stated that FNA cytology combined with clinical presentations (symptoms and endocrine function) and imaging studies (CT scan, MRI and norcholesterol scintigraphy) can increase diagnostic accuracy to 100% (Lumachi, Borsato et al. 2007 ). In addition, other reports stated that image-guided FNA cytology is a safe and sensitive procedure and should be performed in all patients with incidentally discovered adrenal masses with high sensitivity (83.3 -100%), specificity (96.3 -100%), positive predictive value (95.8 -100%), negative predictive value (100%), and accuracy (97.6%) (Fassina, Borsato et al. 2000; Lumachi, Borsato et al. 2003) .
The characteristic FNA cytologic features of myelolipoma are the presence of normal bone marrow hematopoietic cells (megakaryocytes, myeloid cells, and erythrocytic precursors) and mature adipose tissue in variable proportions (Settakorn, Sirivanichai et al. 1999 ) ( Figure  9 ). The differential diagnosis includes well-differentiated liposarcoma and hematopoietic tumors. FNA is an important tool to diagnose adrenal metastases. FNA findings vary depending on the primary site of the metastatic malignancies. Comparison with morphology of the known primary malignancy should be performed. Immunohistochemical stains are very useful in narrowing the differential diagnosis. Adrenal tumors are positive for melan A and inhibin and negative for epithelial membrane antigen (EMA). When FNA smears show abundant inflammatory cells, benign adrenal glandular epithelial cells, necrosis or granulomas, an infectious lesion should be considered. An aliquot of FNA should be sent for culture, or molecular tests, and special stains (GMS, PAS, AFB, FITE, and GRAM) should be ordered on cytospin, smear, or cellblock.
Complications of adrenal FNA biopsy include hypertension, hematoma of liver, thorax and duodenum (Quijano and Drut 1989) , and pneumothorax (Lumachi, Borsato et al. 2007 ).
Immunohistochemistry and special stains
The following special and IHC stains are useful in primary adrenal lesions. Special stains (chloroacetate esterase, myeloid peroxidase) or immunostains (factor VIII) are helpful to confirm the myeloid nature of the immature cells in myelolipoma. Adrenal cortical nonneoplastic and neoplastic cells are positive for inhibin, A103 and melan A, while negative for www.intechopen.com CK7, CK20, and chromogranin. Pheochromocytoma cells are positive for chromogranin, synaptophysin and NSE, and are negative for EMA and cytokeratins. Sustentacular cells are positive for S-100. 
Conclusion
In summary, a nodule or mass found in the endocrine organs should be evaluated thoroughly, no matter with or without clinical symptoms. Based on clinical presentation, past medical history, imaging studies, and laboratory tests, clinicians should evaluate if further investigation by FNA or needle core biopsy with accessory studies (special stains, IHC or molecular studies) is valuable for accurate diagnosis and making decision of suitable therapy (follow-up, surgical excision, chemotherapy including targeted chemotherapy, or radiation). 
